Literature DB >> 20946148

A multi-stage multi-design strategy provides strong evidence that the BAI3 locus is associated with early-onset venous thromboembolism.

G Antoni1, P-E Morange, Y Luo, N Saut, G Burgos, S Heath, M Germain, C Biron-Andreani, J-F Schved, G Pernod, P Galan, D Zelenika, M-C Alessi, L Drouet, S Visvikis-Siest, P S Wells, M Lathrop, J Emmerich, D-A Tregouet, F Gagnon.   

Abstract

BACKGROUND: Factor VIII (FVIII) and von Willebrand factor (VWF) are two known quantitative risk factors for venous thromboembolism (VTE).
OBJECTIVES: To identify new loci that could contribute to VTE susceptibility and to modulating FVIII and/or VWF levels. PATIENTS/
METHODS: A pedigree linkage analysis was first performed in five extended French-Canadian families, including 253 individuals, to identify genomic regions linked to FVIII or VWF levels. Identified regions were further explored using 'in silico' genome-wide association studies (GWAS) data on VTE (419 patients and 1228 controls), and two independent case-control studies (MARTHA and FARIVE) for VTE, gathering 1166 early-onset patients and 1408 healthy individuals. Single nucleotide polymorphisms (SNPs) associated with VTE risk were further investigated in relation to plasma levels of FVIII and VWF in a cohort of 108 healthy nuclear families.
RESULTS: Four main linkage regions were identified, among which the well-characterized ABO locus, the recently identified STAB 2 gene, and a third one, on chromosome 6q13-14, harbouring four non-redundant SNPs, associated with VTE at P < 10(-4) in the GWAS dataset. The association of one of these SNPs, rs9363864, with VTE was further replicated in the MARTHA and FARIVE studies. The rs9363864-AA genotype was associated with a lower risk for VTE (OR = 0.58 [0.42-0.80], P = 0.0005) but mainly in non-carriers of the FV Leiden mutation. This genotype was further found to be associated with the lowest levels of FVIII (P = 0.006) and VWF (P = 0.001).
CONCLUSIONS: The BAI3 locus where the rs9363864 maps is a new candidate for VTE risk.
© 2010 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20946148     DOI: 10.1111/j.1538-7836.2010.04092.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  18 in total

1.  Single nucleotide polymorphisms in an intergenic chromosome 2q region associated with tissue factor pathway inhibitor plasma levels and venous thromboembolism.

Authors:  J Dennis; V Truong; D Aïssi; A Medina-Rivera; S Blankenberg; M Germain; M Lemire; L Antounians; M Civelek; R Schnabel; P Wells; M D Wilson; P-E Morange; D-A Trégouët; F Gagnon
Journal:  J Thromb Haemost       Date:  2016-09-17       Impact factor: 5.824

2.  Robust validation of methylation levels association at CPT1A locus with lipid plasma levels.

Authors:  France Gagnon; Dylan Aïssi; Alain Carrié; Pierre-Emmanuel Morange; David-Alexandre Trégouët
Journal:  J Lipid Res       Date:  2014-05-21       Impact factor: 5.922

3.  Whole-exome sequencing in evaluation of patients with venous thromboembolism.

Authors:  Eun-Ju Lee; Daniel J Dykas; Andrew D Leavitt; Rodney M Camire; Eduard Ebberink; Pablo García de Frutos; Kavitha Gnanasambandan; Sean X Gu; James A Huntington; Steven R Lentz; Koen Mertens; Christopher R Parish; Alireza R Rezaie; Peter P Sayeski; Caroline Cromwell; Noffar Bar; Stephanie Halene; Natalia Neparidze; Terri L Parker; Adrienne J Burns; Anne Dumont; Xiaopan Yao; Cassius Iyad Ochoa Chaar; Jean M Connors; Allen E Bale; Alfred Ian Lee
Journal:  Blood Adv       Date:  2017-06-29

4.  The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity.

Authors:  Laura L Swystun; Jesse D Lai; Colleen Notley; Ilinca Georgescu; A Simonne Paine; Jeff Mewburn; Kate Nesbitt; Kai Schledzewski; Cyrill Géraud; Julia Kzhyshkowska; Sergij Goerdt; Wilma Hopman; Robert R Montgomery; Paula D James; David Lillicrap
Journal:  J Clin Invest       Date:  2018-08-20       Impact factor: 14.808

5.  The ENTPD1 promoter polymorphism -860 A > G (rs3814159) is associated with increased gene transcription, protein expression, CD39/NTPDase1 enzymatic activity, and thromboembolism risk.

Authors:  James P Maloney; Brian R Branchford; Gary L Brodsky; Maxwell S Cosmic; David W Calabrese; Christina L Aquilante; Kelly W Maloney; Joseph R Gonzalez; Weiming Zhang; Kerrie L Moreau; Kerri L Wiggins; Nicholas L Smith; Ulrich Broeckel; Jorge Di Paola
Journal:  FASEB J       Date:  2017-03-16       Impact factor: 5.191

Review 6.  Dissecting the genetic determinants of hemostasis and thrombosis.

Authors:  Karl C Desch
Journal:  Curr Opin Hematol       Date:  2015-09       Impact factor: 3.284

Review 7.  Genetic regulation of plasma von Willebrand factor levels in health and disease.

Authors:  L L Swystun; D Lillicrap
Journal:  J Thromb Haemost       Date:  2018-10-30       Impact factor: 5.824

8.  Genetics of venous thrombosis: insights from a new genome wide association study.

Authors:  Marine Germain; Noémie Saut; Nicolas Greliche; Christian Dina; Jean-Charles Lambert; Claire Perret; William Cohen; Tiphaine Oudot-Mellakh; Guillemette Antoni; Marie-Christine Alessi; Diana Zelenika; François Cambien; Laurence Tiret; Marion Bertrand; Anne-Marie Dupuy; Luc Letenneur; Mark Lathrop; Joseph Emmerich; Philippe Amouyel; David-Alexandre Trégouët; Pierre-Emmanuel Morange
Journal:  PLoS One       Date:  2011-09-27       Impact factor: 3.240

9.  Combined analysis of three genome-wide association studies on vWF and FVIII plasma levels.

Authors:  Guillemette Antoni; Tiphaine Oudot-Mellakh; Apostolos Dimitromanolakis; Marine Germain; William Cohen; Philip Wells; Mark Lathrop; France Gagnon; Pierre-Emmanuel Morange; David-Alexandre Tregouet
Journal:  BMC Med Genet       Date:  2011-08-02       Impact factor: 2.103

10.  Whole-exome sequencing identifies rare variants in STAB2 associated with venous thromboembolic disease.

Authors:  Karl C Desch; Ayse B Ozel; Matt Halvorsen; Paula M Jacobi; Krista Golden; Mary Underwood; Marine Germain; David-Alexandre Tregouet; Pieter H Reitsma; Clive Kearon; Lauren Mokry; J Brent Richards; Frances Williams; Jun Z Li; David Goldstein; David Ginsburg
Journal:  Blood       Date:  2020-07-30       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.